US · MASI
Masimo Corporation
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Irvine, CA 92618
- Website
- masimo.com
Price · as of 2026-01-03
$178.48
Market cap 9.42B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $70.85 | -60.3% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $50.02 | -71.98% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2012 | $0.00 | $21.67 | |||
| 2013 | $10.51 | $19.21 | |||
| 2014 | $11.84 | $19.91 | |||
| 2015 | $13.09 | $24.69 | |||
| 2016 | $41.26 | $126.00 | |||
| 2017 | $26.43 | $47.16 | |||
| 2018 | $34.15 | $56.49 | |||
| 2019 | $39.80 | $62.17 | |||
| 2020 | $45.81 | $128.16 | |||
| 2021 | $47.09 | $67.28 | |||
| 2022 | $30.06 | $186.17 | |||
| 2023 | $25.84 | $13.44 | |||
| 2024 | $0.00 | $0.00 | |||
| 2025 | |||||
| 2026 | $175.40 | $1.15 | $0.00 | $50.02 |
AI valuation
Our deep-learning model estimates Masimo Corporation's (MASI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $178.48
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$70.85
-60.3% upside
Graham-Dodd
—
— upside
Graham Formula
$50.02
-71.98% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MASI | Masimo Corporation | $178.48 | 9.42B | — | -60% | — | -72% | -62.06 | 13.04 | 6.16 | 31.37 | — | 16.55 | 61.90% | 20.30% | -9.92% | — | — | — | 0.72 | — | 2.49 | 1.40 | 1.17 | — | — | — | 2.10% | 0.58 | — | 0.00% | 0.00% | 3.87% | 31.51 | 49.38 | 6.40 | 8.77 |
| ABVX | Abivax S.A. | $121.28 | 7.95B | -67% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | — | 27.39 | 100.00% | -1602.89% | -1633.08% | -148.98% | 2618.19% | -66.22% | 2.40 | -41.33 | 1.84 | 1.72 | 0.27 | -1837.00% | 13354.00% | 5429.00% | -36.31% | -1.66 | 2341.68% | 0.00% | 0.00% | 0.00% | -2.19 | -2.45 | 35.14 | -3.71 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| AVTR | Avantor, Inc. | $9.05 | 6.17B | +191% | -61% | — | — | -11.27 | 1.07 | 0.91 | 68.88 | — | -2.28 | 32.65% | -3.76% | -8.09% | -9.20% | -2.61% | -4.44% | 0.71 | -1.45 | 1.78 | 1.04 | 25.82 | -17500.00% | -341.00% | -2847.00% | 8.29% | 0.45 | 5.24% | 0.00% | 0.00% | 4.92% | -38.81 | 19.30 | 1.46 | 1.37 |
| BAX | Baxter International Inc. | $20.37 | 10.48B | +17% | -61% | — | — | -10.55 | 1.65 | 0.90 | 23.68 | -27.93 | -3.19 | 30.05% | -2.74% | -8.51% | -14.62% | -1.88% | -4.18% | 1.63 | -1.06 | 2.31 | 1.31 | 10.49 | 3780.00% | 572.00% | -4222.00% | 3.20% | 0.28 | 1.97% | 3.45% | -36.40% | 39.56% | -58.89 | 56.15 | 1.61 | 2.13 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| HSIC | Henry Schein, Inc. | $82.39 | 9.99B | +2% | -60% | -90% | -52% | 24.70 | 3.03 | 0.75 | 13.28 | 342.43 | -4.95 | 29.14% | 5.75% | 3.02% | 11.99% | 9.02% | 3.71% | 1.14 | 5.05 | 1.38 | 0.56 | 3.51 | 721.00% | 403.00% | -1331.00% | 5.83% | 0.22 | 8.87% | 0.00% | 0.00% | 8.65% | 17.63 | 23.32 | 1.01 | 2.86 |
| MOH | Molina Healthcare, Inc. | $154.05 | 7.93B | +43% | +423% | -46% | +17% | 16.40 | 1.90 | 0.17 | 7.63 | — | 4.13 | 8.97% | 1.72% | 1.04% | 11.02% | 52.20% | 3.03% | 0.97 | 4.07 | 1.69 | 1.06 | -0.31 | -5632.00% | 1175.00% | -21691.00% | -8.21% | -0.07 | -53.04% | 0.00% | 0.00% | 12.92% | 9.53 | -11.70 | 0.16 | 4.20 |
| RGEN | Repligen Corporation | $128.73 | 7.25B | -26% | -60% | -83% | -84% | 143.73 | 3.34 | 9.52 | 42.30 | — | 11.60 | 47.09% | 8.07% | 6.62% | 2.40% | 2.38% | 1.69% | 0.33 | 2.57 | 8.37 | 6.82 | 0.75 | -28696.00% | 1636.00% | -3410.00% | 1.34% | 0.86 | 4.78% | 0.00% | 0.00% | 0.00% | 116.65 | 74.02 | 9.41 | 5.94 |
| RYTM | Rhythm Pharmaceuticals, I… | $92.73 | 6.19B | -37% | +215% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
| STVN | Stevanato Group S.p.A. | $15.52 | 4.24B | +118% | -45% | -52% | -68% | 31.27 | 3.57 | 4.54 | 21.56 | — | 3.80 | 27.38% | 14.60% | 10.67% | 12.64% | 7.41% | 7.29% | 0.31 | 23.48 | 1.84 | 1.32 | 1.33 | -2182.00% | 172.00% | -5314.00% | -3.15% | 0.33 | -9.88% | 0.29% | 9.00% | 0.29% | 33.16 | -33.86 | 4.84 | 4.68 |
About Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
- CEO
- Catherine Szyman
- Employees
- 3.6K
- Beta
- 1.26
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($70.85 ÷ $178.48) − 1 = -60.3% (DCF, example).